依达拉奉右莰醇联合丁苯酞对血管内治疗前循环脑梗塞开通良好患者脑保护的疗效  

EFFECT OF EDARAVONE DEXCAMORNIOL COMBINED WITH BUTYLPHALIDE ON CEREBRAL PROTECTION IN PATIENTS WITH CEREBRAL INFARCTION OF ANTERIOR CIRCULATION WITH GOOD CIRCULATION AFTER ENDOVASCULAR TREATMENT

作　　者：朱丽霞[1] 高健 柳桂红 李冠霞 董晓柳[1] 屈海宏[1] ZHU Lixia;GAO Jian;LIU Guihong;LI Guanxia;DONG Xiaoliu;QU Haihong(Tangshan People’s Hospital,TangShan 063000,China)

机构地区：[1]河北省唐山市人民医院,063000

出　　处：《中国煤炭工业医学杂志》2022年第6期629-633,共5页Chinese Journal of Coal Industry Medicine

基　　金：2019年度河北省医学科学研究课题计划(编号:20191594)。

摘　　要：目的 探讨依达拉奉右莰醇联合丁苯酞对血管内治疗前循环脑梗塞开通良好患者脑保护的疗效。方法选择2020年10月—2021年12月唐山市人民医院神经内科收治的80例前循环急性脑梗塞患者为观察对象进行回顾性研究,依据采取的治疗方法不同分为对照组40例和观察组40例。对照组给予血管内支架取栓治疗及常规基础治疗。观察组给予血管内支架取栓治疗并在此基础上联合应用依达拉奉右崁醇注射液15 ml+生理盐水100 ml,2次/d静脉滴注;丁苯酞注射液100 ml(含丁苯酞成份25 mg),2次/d静脉滴注;比较二组患者治疗2周后美国国立卫生研究院卒中量表(NIHSS)评分、格拉斯哥预后(GOS)评分、改良Rankin(mRS)评分差别;比较二组患者治疗2周后细胞炎症因子肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)区别;比较二组患者治疗2周后恶心、呕吐、头痛、头晕等术后不良反应、并发症情况。比较二组患者治疗2周后治疗效果情况。结果 二组治疗前NIHSS评分、mRS评分及GOS评分比较差异均无统计学意义(P>0.05);二组患者治疗2周后观察组NIHSS评分、mRS评分低于对照组,而GOS评分在治疗后则高于对照组,差异均具有统计学意义(P<0.05);二组患者治疗2周后观察组细胞炎症因子肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)明显低于对照组,差异有统计学意义(P<0.05);二组患者治疗2周后观察组治疗效果(总有效率)明显好于对照组,差异有统计学意义(P<0.05);二组患者治疗2周后观察组出现恶心、呕吐、头痛、头晕等术后不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论 依达拉奉右莰醇联合丁苯酞对血管内治疗前循环脑梗塞开通良好患者可提供良好的脑保护作用,从而改善预后,提高治疗效果,降低炎性细胞因子反应,降低术后不良反应,值得临床推广。Objective To investigate the effect of edaravone dexcamferol combined with butylphthalide on brain protection in patients with cerebral infarction of anterior circulation with good circulation after endovascular treatment.Methods A total of eighty patients with anterior circulation acute cerebral infarction admitted to Department of Neurology,Tangshan People’s Hospital from October 2020 to December 2021 as the observation objects were selected for a retrospective study.According to the different treatment methods,forty cases in the control group and forty cases in the observation group.The control group was treated with endovascular stent thrombectomy and conventional basic treatment.The observation group was treated with endovascular stent thrombectomy,and on this basis,edaravone rholkanol injection 15 ml+ normal saline 100 ml,twice a day by intravenous infusion.Butylphthalide injection 100 ml(containing 25 mg butylphthalide component),twice a day intravenous drip.The National Institutes of Health Stroke Scale(NIHSS) score,Glasgow Outcome Scale(GOS) score and modified Rankin(mRS) score were compared between the two groups after 2 weeks of treatment.The differences of cellular inflammatory factors tumor necrosis factor(TNF-α) and interleukin-6(IL-6) were compared between the two groups after 2 weeks of treatment.Postoperative adversereactions and complications such as nausea,vomiting,headache and dizziness were compared between the two groups after 2 weeks of treatment.The treatment effect was compared between the two groups after 2 weeks of treatment.Results There were no significant differences in NIHSS score,mRS score and GOS score between the two groups before treatment(P>0.05).After 2 weeks of treatment,the NIHSS score and mRS score of the observation group were lower than those of the control group,while the GOS score was higher than that of the control group,and the differences were statistically significant(P<0.05).After 2 weeks of treatment,the inflammatory cytokines tumor necrosis factor(TNF-α) and

关 键 词：依达拉奉右莰醇 丁苯酞 血管内治疗 前循环脑梗塞 

分 类 号：R743[医药卫生—神经病学与精神病学]